KIORA PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Contingency, Percent
KIORA PHARMACEUTICALS, INC. (KPRX) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Percent of -0.26% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax contingency, percent for fiscal 2025 was -0.26%.
- KIORA PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax contingency, percent for fiscal 2024 was -3.46%.
- KIORA PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax contingency, percent for fiscal 2023 was -3.36%.
- KIORA PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax contingency, percent for fiscal 2022 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent 12 month |
|---|---|
| 2025-12-31 | -0.26% 10-K · filed 2026-03-25 |
| 2024-12-31 | -3.46% 10-K · filed 2026-03-25 |
| 2023-12-31 | -3.36% 10-K · filed 2025-03-25 |
| 2022-12-31 | 0.00% 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |